nach oben

Medical Microbiology and Immunology

Erschienen in:

01.05.2005 | Opinion

Bioterrorism: is it a real threat?

verfasst von: René Gottschalk, Wolfgang Preiser

Erschienen in: Medical Microbiology and Immunology | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

The Geneva Protocol of 1925 commits the signatory nations to refraining from the use of biological weapons. However, the terrorist assaults of September 2001 and, subsequently, the anthrax-containing letters are cause for great concerns: new threats to the security of nations are expected, as terrorist organizations seem to increasingly explore novel ways of spreading terror.

In this context, naturally emerging diseases such as SARS, monkeypox or West Nile fever assume new importance because it is difficult to distinguish between natural epidemics and possible bioweapon assaults. Great efforts on the part of governments and public health authorities are necessary to counteract these threats.

Beeching NJ, Dance DAB, Miller ARO, Spencer RC (2002) Biological warfare and bioterrorism. Br Med J 324:336–339CrossRef

Berger A, Drosten C, Doerr HW, Stürmer M, Preiser W (2004) Severe acute respiratory syndrome (SARS)—paradigm of an emerging viral infection. J Clin Virol. 29:13–22

Bravata DM, Sundaram V, McDonald KM, Smith WM, Szeto H, Schleinitz MD, Owens DK (2004) Evaluating detection and diagnostic decision support systems for bioterrorism response. Emerg Infect Dis 10:100–108

Bundesministerium für Gesundheit und Soziale Sicherung (BMGS) Pressemitteilung 4/2003. Available at: http://www.bmgs.bund.de/deu/gra/aktuelles/pm/bmgs03/bmgs4_4340.cfm (accessed 25 May 2004)

Bush LM, Abrams BH, Beall A, Johnson CC (2001) Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 345:1607–1610CrossRefPubMed

Casadevall A, Pirofski LA (2004) The weapon potential of a microbe. Trends Microbiol 12:259–263PubMed

Centers for Disease Control and Prevention (1999) Outbreak of West Nile-like viral encephalitis—New York, 1999. MMWR Morb Mortal Wkly Rep 48:845–849PubMed

Centers for Disease Control and Prevention (2001) Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 50:889–893PubMed

Centers for Disease Control and Prevention (2003) Bioterrorism Agents/Diseases; last modification November 19, 2003. Available at: http://www.bt.cdc.gov/agent/agentlist-category.asp (accessed 25 May 2004)

10.

Centers for Disease Control and Prevention (2003) Smallpox vaccination and adverse reactions: guidance for clinicians. MMWR Morb Mortal Wkly Rep 52:1–28

11.

Centers for Disease Control and Prevention (2004) 2003 West Nile virus activity in the United States (reported as of May 21, 2004). Available from http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount03_detailed.htm (accessed 12 July 2004)

12.

Di Giulio DB, Eckburg PB (2004) Human monkeypox: an emerging zoonosis. Lancet Infect Dis 4:15–25CrossRefPubMed

13.

Dye C, Gay N (2003) Epidemiology: Modeling the SARS epidemic. Science 300:1884–1885CrossRefPubMed

14.

Farber NJ, Aboff BM, Weiner J, Davis EB, Boyer EG, Ubel PA (2001) Physicians’ willingness to participate in the process of lethal injection for capital punishment. Ann Intern Med 135:884–888PubMed

15.

Fenner F, Henderson DA, Arita I, Ježek Z, Ladnyi ID (1988) Developments in vaccination and control between 1900 and 1966. In: Smallpox and its eradication, chapter 7. World Health Organization, Geneva

16.

Guarner J, Johnson BJ, Paddock CD, Shieh WJ, Goldsmith CS, Reynolds MG, Damon IK, Regnery RL, Zaki SR, the Veterinary Monkeypox Virus Working Group (2004) Monkeypox transmission and pathogenesis in prairie dogs. Emerg Infect Dis 10:426–431

17.

Jernigan DB, Raghunathan PL, Bell BP, et al (2002) Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8:1019–1028PubMed

18.

Jia XY, Briese T, Jordan I, Rambaut A, Chi HC, Mackenzie JS, Hall RA, Scherret J, Lipkin WI (1999) Genetic analysis of West Nile New York 1999 encephalitis virus. Lancet 354:1971–1972CrossRefPubMed

19.

Kelley M, Coghlan J (2003) Mixing bugs and bombs. Bull Atom Sci 59:24–31

20.

Lanciotti RS, Roehrig JT, Deubel V, et al (1999) Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286:2333–2337CrossRefPubMed

21.

Ludwig B, Kraus FB, Allwinn R, Doerr HW, Preiser W (2003) Viral zoonoses—a threat under control? Intervirology 46:71–78CrossRefPubMed

22.

Monaghan K (2003) SARS down but still a threat. National Intelligence Council Intelligence Community Assessment, August 2003. Available at: http://www.cia.gov/nic/special_sarsthreat.html (accessed 25 May 2004)

23.

Müllbacher A, Lobigs M (2001) Creation of killer poxvirus could have been predicted. J Virol 75:8353–8355CrossRefPubMed

24.

Nash D, Mostashari F, Fine A, et al (2001) The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 344:1807–1814CrossRefPubMed

25.

Petro JB, Plasse TR, Mcnulty JA (2003) Biotechnology: impact on biological warfare and biodefense. Biosecur Bioterror 1:161–168CrossRefPubMed

26.

Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (Geneva Protocol, 1925). Opened for signature: 17 June 1925, entered into force: 8 February 1928. Available at: http://www.sussex.ac.uk/spru/hsp/Genev-Prot.html (accessed 21 June 2004)

27.

Reed KD, Melski JW, Graham MB, et al (2004) The detection of monkeypox in humans in the Western hemisphere. N Engl J Med. 350:342–350

28.

Richardson L (2004) Buying biosafety—is the price right? N Engl J Med 350:2121–2123

29.

Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM (2002) Public health assessment of potential biological terrorism agents. Emerg Infect Dis 8:225–230PubMed

30.

Rumyantsev SN (2004) The best defence against bioweapons has already been invented by evolution. Infect Genet Evol 4:159–166PubMed

31.

Spencer RC, Lightfoot NF (2001) Preparedness and response to bioterrorism. J Infect 43:104–110CrossRefPubMed

32.

Takahashi H, Keim P, Kaufmann AF, Keys C, Smith KL, Taniguchi K, Inouye S, Kurata T (2004) Bacillus anthracis incident, Kameido, Tokyo, 1993. Emerg Infect Dis 10:117–120

33.

The European Agency for the Evaluation of Medicinal Products (2002) EMEA/CPMP guidance document on use of medicinal products for treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism. CPMP/4048/01. Available at: http://www.emea.eu.int/htms/human/bioterror/bioterror.htm (accessed 18 July 2004)

34.

Wirtz A, Gottschalk R, Weber HJ (2003) Management of an attack with biological agents. Reflections on the necessary infrastructure for states and towns. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 46:1001–1009CrossRef

35.

World Health Organization (2002) Smallpox eradication: destruction of variola virus stocks. Report by the Secretariat. Available at: http://www.who.int/gb/ebwha/pdf_files/WHA55/ea5521.pdf (accessed 25 May 2004)

36.

World Health Organization (2003) Laboratory safety manual. Second edition (revised). WHO/CDS/CSR/LYO/2003.4. Interim guidelines. World Health Organization, Geneva 2003

37.

World Health Organization (2004) Public health response to biological and chemical weapons: WHO guidance, 2nd edn. World Health Organization, Geneva 2004. Available at: http://www.who.int/csr/delibepidemics/biochemguide/en/ (accessed 18 July 2004)

Titel: Bioterrorism: is it a real threat?
verfasst von: René Gottschalk
Wolfgang Preiser
Publikationsdatum: 01.05.2005
Verlag: Springer-Verlag
Erschienen in: Medical Microbiology and Immunology / Ausgabe 3/2005
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-004-0228-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia

Mutations in Sendai virus variant F1-R that correlate with plaque formation in the absence of trypsin

Increased early local immune responses and altered worm development in high-dose infections of mice susceptible to the filaria Litomosoides sigmodontis

Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d

Complement C3 is required for the progression of cutaneous lesions and neutrophil attraction in Leishmania major infection